Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AZD4831 (Mitiperstat) on Midazolam PK in Healthy Subjects
NCT05052710Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration time curve from zero to infinity, Area under the plasma concentration curve from zero to the last quantifiable concentration and 1 more. Started Oct 2021; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05052710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052710.